Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $12.2 million
Deal Type : Series B Financing
Boehringer, Novo-backed German biotech banks €11M in liver regeneration push
Details : The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $12.2 million
Deal Type : Series B Financing